Cogent Biosciences, Inc. Deferred Revenue, Revenue Recognized
Cogent Biosciences, Inc. (COGT) reported Deferred Revenue, Revenue Recognized of $2.00 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-13.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2018-11-13
- Cogent Biosciences, Inc. deferred revenue, revenue recognized for the quarter ending 2018-09-30 was $2.00M.
- Cogent Biosciences, Inc. deferred revenue, revenue recognized for the quarter ending 2018-06-30 was $1.70M.
- Cogent Biosciences, Inc. deferred revenue, revenue recognized for the quarter ending 2018-03-31 was $2.20M.
| Period end | Deferred Revenue, Revenue Recognized 3 month | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 9 month |
|---|---|---|---|
| 2018-09-30 | $2.00M 10-Q · filed 2018-11-13 | $5.90M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $1.70M 10-Q · filed 2018-08-13 | $3.90M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $2.20M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |